Asterias obtains IP estate related to ischemic stroke from University of California. Plus Apeiron, Qualigen, Biovaxys and AbbVie turn to academic partners for early-stage cancer assets.
Shortly after arriving at University of California, San Diego as its director of commercialization, Ruben Dario Flores-Saaib initiated an “entrepreneurs in residence” program that in two years helped spur the creation of five start-ups around research conducted at the school.
Flores-Saaib, a 12-year biopharma industry veteran who helped establish and lead a bioscience academic alliances team at Merck KGAA/
Licensing a BTK inhibitor for progressive MS previously held by Biogen, Zenas says Phase III orelabrutinib can stave off disability related with disease progression.
The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.
Chiesi and the Boston-area biotech will co-develop a CRISPR-Cas gene-editing therapy for primary hyperoxaluria type 1. They hope to provide a curative therapy for the rare disease.
Plus deals involving Klotho/Turn, BioLineRx/Hemispherian, Dogwood/Serpin, Harrow/Melt, Gossamer/Respira, Lilly/Prellis, BI/TegMine and more.
The company announced positive Phase II data for umedaptanib pegol and plans to move it into Phase III development in fiscal year 2026.
The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.
Raising UK drug prices and offering lower list prices only to those US patients who are under- or uninsured were the industry’s initially cosmetic answers to the administration’s most favored nation drug pricing challenge. Then Pfizer stepped in.
